Introduction
LL-37 is the only known member of the cathelicidin family of antimicrobial peptides expressed in humans. It is a 37-amino acid cationic peptide derived from the C-terminal cleavage of the precursor protein hCAP18 (human cationic antimicrobial protein-18). LL-37 plays important roles in innate immunity, wound healing, and immune modulation, and has been the subject of extensive research across infectious disease, dermatology, and oncology.
Structure and Production
LL-37 is produced primarily by neutrophils, mast cells, natural killer cells, monocytes, and epithelial cells throughout the body. It is particularly concentrated at sites of infection and injury. The peptide is amphipathic — having both hydrophobic and hydrophilic regions — which is essential to its membrane-disrupting antimicrobial mechanism. At physiological concentrations it forms alpha-helical structures that can insert into and disrupt bacterial cell membranes.
Antimicrobial Mechanism
LL-37’s primary antimicrobial mechanism involves electrostatic attraction to negatively charged bacterial membranes (bacterial membranes carry a net negative charge while mammalian cell membranes are relatively neutral). Upon binding, LL-37 forms pores or disrupts the structural integrity of the bacterial membrane, leading to membrane depolarization and bacterial death. This mechanism is effective against a broad spectrum of bacteria including both gram-positive and gram-negative species, as well as some fungi and viruses.
Broad Spectrum Activity
Research has demonstrated LL-37 activity against numerous pathogens including: Staphylococcus aureus (including MRSA), Pseudomonas aeruginosa, Escherichia coli, Candida albicans, and various respiratory viruses. Its activity against MRSA has attracted particular research attention given the clinical challenge of antibiotic-resistant infections.
Immunomodulatory Functions
Beyond direct antimicrobial activity, LL-37 serves important immunomodulatory roles. It promotes recruitment of immune cells to infection sites, modulates inflammatory cytokine production, activates dendritic cells, and influences adaptive immune responses. Research has shown LL-37 can both amplify and dampen immune responses depending on context, acting as a complex immune regulator rather than a simple pro-inflammatory signal.
Wound Healing Research
LL-37 has been studied for its role in wound healing, where it promotes keratinocyte migration, angiogenesis, and re-epithelialization. These properties have generated research interest in LL-37 as a potential therapeutic for chronic wound conditions where healing is impaired.
Oncology Research
LL-37’s role in cancer biology is complex and context-dependent. Some research has found tumor-suppressive activity, particularly in colorectal cancer models. Other studies have found pro-tumorigenic effects in breast cancer and some other cancer types. This bidirectional relationship with cancer biology is an active area of investigation.
Conclusion
LL-37 is a multifunctional host defense peptide with antimicrobial, immunomodulatory, and wound healing activities. Its research profile spans infectious disease, dermatology, and oncology, making it one of the most broadly studied antimicrobial peptides. Its potential applications in antibiotic-resistant infection research and wound healing continue to drive significant research investment.